Brain endothelial cells as pharmacological targets in brain tumors

Molecular Neurobiology

Volumn 30, Issue 2, 2004, Pages 157-183

  Demeule, Michel ^a   Régina, Anthony ^a   Annabi, Borhane ^a   Bertrand, Yanick ^a   Bojanowski, Michel W ^b   Béliveau, Richard ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Antiangiogenesis; Blood brain barrier; Bone marrow stromal cells; Brain tumors; Drug delivery; Endothelial cells; Irradiation

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BIRICODAR; CARMUSTINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DOCETAXEL; EPIGALLOCATECHIN GALLATE; GEMCITABINE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; GREEN TEA EXTRACT; IRINOTECAN; LANIQUIDAR; LARIQUIDAR; NITROSOUREA DERIVATIVE; ONT 093; PACLITAXEL; POLYPHENOL DERIVATIVE; ROFECOXIB; SEMAXANIB; TARIQUIDAR; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VATALANIB; VERAPAMIL; ZOSUQUIDAR;

ALZHEIMER DISEASE; ANTIANGIOGENIC ACTIVITY; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN REGION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GENE THERAPY; GLIOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHENOTYPE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STROKE; UPREGULATION; VIRUS ENCEPHALITIS; ANIMAL; BRAIN; CYTOLOGY; DRUG EFFECT; METABOLISM; METHODOLOGY; PATHOLOGY; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 16644367919     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:30:2:157     Document Type: Review

References (182)

1. Ribatti D., Nico B., Vacca A., Roncali L., Dammacco F. (2002). Endothelial cell heterogeneity and organ specificity. J. Hematother. Stem. Cell Res. 11, 81-90.
2. Ghitescu L., Robert M. (2002). Diversity in unity: the biochemical composition of the endothelial cell surface varies between the vascular beds. Microsc. Res. Tech. 57, 381-389.
3. Aird W. C. (2003). Endothelial cell heterogeneity. Crit. Care Med. Apr. 31, S221-S230.
4. Pardridge W. M. (1999). Blood-brain barrier biology and methodology. J. Neurovirol. 5, 556-569.
5. Kusuhara H., Sugiyama Y. (2001). Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 1). Drug Discov. Today 6, 150-156.
6. Kusuhara H., Sugiyama Y. (2001). Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 2). Drug Discov. Today 6, 206-212.
7. Tsuji A., Tamai I., I. (1999). Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 277-290.
8. Dehouck B., Fenart L., Dehouck M. P., Pierce A., Torpier G., Cecchelli R. (1997). A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138, 877-889.
9. Fillebeen C., Descamps L., Dehouck M. P., et al. (1999). Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J. Biol. Chem. 274, 7011-7017.
10. Habgood M. D., Begley D. J., Abbott N. J. (2000). Determinants of passive drug entry into the central nervous system. Cell Mol. Neurobiol. 20, 231-253.
11. van Asperen J., Mayer U., van Tellingen O., Beijnen J. H. (1997). The functional role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci. 86, 881-884.
12. Schinkel A. H. (1999). P-glycoprotein, a gate-keeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 179-194.
13. Banks W. A. (1999). Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative diseases. J. Neurvirol. 5, 538-555.
14. Fleischhack G., Reif S., Hasan C., Jaehde U., Hettmer S., Bode U. (2001). Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br. J. Cancer 84, 1453-1459.
15. Gregor A., Lind M., Newman H., et al. (1999). Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group. J. Neurooncol. 44, 137-145.
16. Borlongan C. V., Emerich D. F. (2003). Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: Laboratory and preliminary clinical evidence from bradykinin receptor agonist. Cereport. Brain Res. Bull. 60, 297-306.
17. Zhou R., Mazurchuk R., Straubinger R. M. (2002). Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res. 62, 2561-2566.
18. Brigger I., Morizet J., Aubert G., et al. (2002). Poly(ethylene glycol)-coated hexadecylcyano-acrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 303, 928-936.
19. Cornford E. M., Cornford M. E. (2002). New systems for delivery of drugs to the brain in neurological disease. Lancet Neurol. 1, 306-315.
20. Demeule M., Poirier J., Jodoin J., et al. (2002). High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. 83, 924-933.
21. Bickel U., Yoshikawa T., Pardridge W. M. (2001). Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46, 247-279.
22. Derossi D., Joliot A. H., Chassaing G., Prochiantz A. (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269, 10,444-10,450.
23. Pooga M., Kut C., Kihlmark M., et al. (2001). Cellular translocation of proteins by transportan. FASEB J. 15, 1451-1453.
24. Drin G., Rousselle C., Scherrmann J. M., Rees A. R., Temsamani J. (2002). Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS. Pharm. Sci. 4, 26.
25. Fawell S., Seery J., Daikh Y., et al. (1994). Tatmediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91, 664-668.
26. Schwarze S. R., Ho A., Vocero-Akbani A., Dowdy S. F. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569-1572.
27. Wu D., Pardridge W. M. (1998). Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. Drug Metab. Dispos. 26, 937-939.
28. Wu D., Song B. W., Vinters H. V., Pardridge W. M. (2002). Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J. Drug Target. 10, 239-245.
29. Pardridge W. M. (2001). Brain drug targeting and gene technologies. Jpn. J. Pharmacol. 87, 97-103.
30. Huber J. D., Egleton R. D., Davis T. P. (2001). Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends. Neurosci. 24, 719-725.
31. Buee L., Hof P. R., Bouras C., et al. (1994). Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol. (Berl.) 87, 469-480.
32. Jancso G., Domoki F., Santha P., et al. (1998). Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci. Lett. 253, 139-141.
33. Mattila K. M., Pirttila T., Blennow K., Wallin A., Viitanen M., Frey H. (1994). Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol. Scand. 89, 192-198.
34. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. (1996). beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171.
35. Horani M. H., Mooradian A. D. (2003). Effect of diabetes on the blood-brain barrier. Curr. Pharm. Des. 9, 833-840.
36. Wardlaw J. M., Sandercock P. A., Dennis M. S., Starr J. (2003). Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 34, 806-812.
37. Behin A., Hoang-Xuan K., Carpentier A. F., Delattre J. Y. (2003). Primary brain tumours in adults. Lancet 361, 323-331.
38. Sawaya R. (1999). Extent of resection in malignant gliomas: a critical summary. J. Neurooncol. 42, 303-305.
39. Jolesz F. A., Talos I. F., Schwartz R. B., et al. (2002). Intraoperative magnetic resonance imaging and magnetic resonance imaging-guided therapy for brain tumors. Neuroimaging. Clin. N. Am. 12, 665-683.
40. Kleihues P., Ohgaki H. (1999). Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncology 1, 44-51.
41. Berg G., Blomquist E., Cavallin-Stahl E. (2003). A systematic overview of radiation therapy effects in brain tumours. Acta. Oncol. 42, 582-588.
42. Karim A. B., Afra D., Cornu P., et al. (2002). Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult. European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council Study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52, 316-324.
43. Deangelis L. M. (2003). Benefits of adjuvant chemotherapy in high-grade gliomas. Semin. Oncol. 30, 15-18.
44. Westphal M., Hilt D. C., Bortey E., et al. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncology 5, 79-88.
45. Sansur C. A., Chin L. S., Ames J. W., et al. (2000). Gamma knife radiosurgery for the treatment of brain metastases. Stereotact. Funct. Neurosurg. 74, 37-51.
46. Gerosa M., Nicolato A., Foroni R. (2003). The role of gamma knife radiosurgery in the treatment of primary and metastatic brain tumors. Curr. Opin. Oncol. 15, 188-196.
47. Jaeckle K. A., Hess K. R., Yung W. K., et al. (2003). Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. J. Clin. Oncol. 21, 2305-2311.
48. Marras C., Mendola C., Legnani F. G., DiMeco F. (2003). Immunotherapy and biological modifiers for the treatment of malignant brain tumors. Curr. Opin. Oncol. 15, 204-208.
49. Folkman J., Klagsbrun M. (1987). Angiogenic factors. Science 235, 442-447.
50. Folkman J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18.
51. O'Reilly M. S., Holmgren L., Shing Y., et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
52. Cao Y., Chen A., An S. S., Ji R. W., Davidson D., Llinas M. (1997). Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem. 272, 22,924-22,928.
53. O'Reilly M. S., Boehm T., Shing Y., et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
54. Kamphaus G. D., Colorado P. C., Panka D. J., et al. (2000). Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275, 1209-1215.
55. Maeshima Y., Colorado P. C., Torre A., et al. (2000). Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275, 21,340-21,348.
56. Yi M., Ruoslahti E. (2001). A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc. Natl. Acad. Sci. USA 98, 620-624.
57. Clapp C., Martial J. A., Guzman R. C., Rentier-Delure F., Weiner R. I. (1993). The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133, 1292-1299.
58. Brooks P. C., Silletti S., von Schalscha T. L., Friedlander M., Cheresh D. A. (1998). Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92, 391-400.
59. Pike S. E., Yao L., Jones K. D., et al. (1998). Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med. 188, 2349-2356.
60. Cao Y., Cao R. (1999). Angiogenesis inhibited by drinking tea. Nature 398, 381.
61. Strik H. M., Schluesener H. J., Seid K., Meyermann R., Deininger M. H. (2001). Localization of endostatin in rat and human gliomas. Cancer 91, 1013-1019.
62. Morimoto T., Aoyagi M., Tamaki M., et al. (2002). Increased levels of tissue endostatin in human malignant gliomas. Clin. Cancer Res. 8, 2933-2938.
63. McCarty M. F., Liu W., Fan F., et al. (2003). Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends. Mol. Med. 9, 53-58.
64. Wang J. L., Liu Y. H., Lee M. C., et al. (2000). Identification of tumor angiogenesis-related genes by subtractive hybridization. Microvasc. Res. 59, 394-397.
65. Aitkenhead M., Wang S. J., Nakatsu M. N., Mestas J., Heard C., Hughes C. C. (2002). Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc. Res. 63, 159-171.
66. Wary K. K., Thakker G. D., Humtsoe J. O., Yang J. (2003). Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol. Cancer 2, 25.
67. Favre C. J., Mancuso M., Maas K., Mclean J. W., Baluk P., Mcdonald D. M. (2003). Expression of genes involved in vascular development and angiogenesis in endothelial cells freshly isolated from adult lungs. Am. J. Physiol. Heart. Circ. Physiol. 285, H1917-H1938.
68. Yang R. B., Ng C. K., Wasserman S. M., et al. (2002). Identification of a novel family of cell-surface proteins expressed in human vascular endothelium. J. Biol. Chem. 277, 46,364-46,373.
69. Shusta E. V., Boado R. J., Pardridge W. M. (2002). Vascular proteomics and subtractive antibody expression cloning. Mol. Cell Proteomics. 1, 75-82.
70. Boado R. J., Li J. Y., Pardridge W. M. (2000). Selective Lutheran glycoprotein gene expression at the blood-brain barrier in normal brain and in human brain tumors. J. Cereb. Blood Flow Metab. 20, 1096-1102.
71. St Croix B., Rago C., Velculescu V., et al. (2000). Genes expressed in human tumor endothelium. Science 289, 1197-1202.
72. Papadopoulos M. C., Saadoun S., Davies D. C., Bell B. A. (2001). Emerging molecular mechanisms of brain tumour oedema. Br. J. Neurosurg. 15, 101-108.
73. Boado R. J., Black K. L., Pardridge W. M. (1994). Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res. Mol. Brain Res. 27, 51-57.
74. Sonoda Y., Kanamori M., Deen D. F., Cheng S. Y., Berger M. S., Pieper R. O. (2003). Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis. Cancer Res. 63, 1962-1968.
75. Carmeliet P., Jain R. K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
76. Yancopoulos G. D., Davis S., Gale N. W., Rudge J. S., Wiegand S. J., Holash J. (2000). Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248.
77. Tse V., Xu L., Yung Y. C., et al.: 4th (2003). The temporal-spatial expression of VEGF, angiopoietins-1 and 2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture. Neurol Res. 25(7), 729-738.
78. Demeule M., Labelle M., Régina A., Berthelet F., Béliveau R. (2001). Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms. Biochem. Biophys. Res. Commun. 281, 827-834.
79. Kruse C. A., Molleston M. C., Parks E. P., Schiltz P. M., Kleinschmidt-DeMasters B. K., Hickey W. F. (1994). A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J. Neurooncol. 22, 191-200.
80. Peoc'h M., Le Duc G., Trayaud A., et al. (1999). Quantification and distribution of neovascularization following microinjection of C6 glioma cells in rat brain. Anticancer Res. 19, 3025-3030.
81. Beranek J. T. (2002). Endothelial hyperplasia: an important indicator of actual angiogenesis. Br. J. Cancer 86, 658.
82. Regina A., Demeule M., Berube A., Moumdjian R., Berthelet F., Beliveau R. (2003). Differences in multidrug resistance phenotype and matrix metalloproteinases activity between endothelial cells from normal brain and glioma. J. Neurochem. 84, 316-324.
83. Cordon-Cardo C., O'Brien J. P., Casals D., et al. (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86, 695-698.
84. Smit J. J., Schinkel A. H., Oude E. R., et al. (1993). Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75, 451-462.
85. Schinkel A. H., Smit J. J., van Tellingen O., et al. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502.
86. Schinkel A. H. (1997). The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 8, 161-170.
87. Schinkel A. H. (1998). Pharmacological insights from P-glycoprotein knockout mice. Int. J. Clin. Pharmacol. Ther. 36, 9-13.
88. Karssen A. M., Meijer O. C., van d. S. I., et al. (2001). Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142, 2686-2694.
89. Karssen A. M., Meijer O. C., van d. S. I., De Boer A. G., De Lange E. C., De Kloet E. R. (2002). The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J. Endocrinol. 175, 251-260.
90. Debry P., Nash E. A., Neklason D. W., Metherall J. E. (1997). Role of multidrug resistance P-glycoproteins in cholesterol esterification. J. Biol. Chem. 272, 1026-1031.
91. Zhang L., Sachs C. W., Fu H. W., Fine R. L., Casey P. J. (1995). Characterization of prenyl-cysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells. J. Biol. Chem. 270, 22,859-22,865.
92. Lam F. C., Liu R., Lu P., et al. (2001). beta-Amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76, 1121-1128.
93. Demeule M., Regina A., Jodoin J., et al. (2002). Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul. Pharmacol. 38, 339-348.
94. Toth K., Vaughan M. M., Peress N. S., Slocum H. K., Rustum Y. M. (1996). MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol. 149, 853-858.
95. Sawada T., Kato Y., Sakayori N., Takekawa Y., Kobayashi M. (1999). Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathol. 16, 23-27.
96. Sawada T., Kato Y., Kobayashi M., Takekekawa Y. (2000). Immunohistochemical study of tight junction-related protein in neovasculature in astrocytic tumor. Brain Tumor Pathol. 17, 1-6.
97. Bertossi M., Virgintino D., Maiorano E., Occhiogrosso M., Roncali L. (1997). Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct. Pathol. 21, 41-49.
98. Regina A., Koman A., Piciotti M., et al. (1998). Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Neurochem. 71, 705-715.
99. Seetharaman S., Maskell L., Scheper R. J., Barrand M. A. (1998). Changes in multidrug transporter protein expression in endothelial cells cultured from isolated human brain microvessels. Int. J. Clin. Pharmacol. Ther. 36, 81-83.
100. Arosarena O., Guerin C., Brem H., Laterra J. (1994). Endothelial differentiation in intracerebral and subcutaneous experimental gliomas. Brain Res. 640, 98-104.
101. Spiegl-Kreinecker S., Buchroithner J., Elbling L., et al. (2002). Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J. Neurooncol. 57, 27-36.
102. Decleves X., Fajac A., Lehmann-Che J., et al. (2002). Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int. J. Cancer 98, 173-180.
103. Demeule M., Shedid D., Beaulieu E., et al. (2001). Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int. J. Cancer 93, 62-66.
104. Thomas H., Coley H. M. (2003). Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control. 10, 159-165.
105. Plow E. F., Herren T., Redlitz A., Miles L. A., Hoover-Plow J. L. (1995). The cell biology of the plasminogen system. FASEB J. 9, 939-945.
106. Pepper M. S. (2001). Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21, 1104-1117.
107. Graham C. H., Fitzpatrick T. E., McCrae K. R. (1998). Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 91, 3300-3307.
108. Cavallaro U., Tenan M., Castelli V., et al. (2001). Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: relevance to the regulation of angiogenesis. J. Cell Biochem. 82, 619-633.
109. VanMeter T. E., Rooprai H. K., Kibble M. M., Fillmore H. L., Broaddus W. C., Pilkington G. J. (2001). The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J. Neurooncol. 53, 213-235.
110. Birkedal-Hansen H. (1995). Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7, 728-735.
111. Forget M. A., Desrosiers R. R., Beliveau R. (1999). Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can. J. Physiol. Pharmacol. 77, 465-480.
112. Vince G. H., Wagner S., Pietsch T., et al. (1999). Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas. Int. J. Dev. Neurosci. 17, 437-445.
113. Raithatha S. A., Muzik H., Rewcastle N. B., Johnston R. N., Edwards D. R., Forsyth P. A. (2000). Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncology 2, 145-150.
114. Friedberg M. H., Glantz M. J., Klempner M. S., Cole B. F., Perides G. (1998). Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 82, 923-930.
115. Killion J. J., Radinsky R., Fidler I. J. (1998). Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 17, 279-284.
116. Egidy G., Eberl L. P., Valdenaire O., et al. (2000). The endothelin system in human glioblastoma. Lab. Invest. 80, 1681-1689.
117. Hansen-Schwartz J., Szok D., Edvinsson L. (2002). Expression of ET(A) and ET(B) receptor mRNA in human cerebral arteries. Br. J. Neurosurg. 16, 149-153.
118. Bagnato A., Spinella F. (2003). Emerging role of endothelin-1 in tumor angiogenesis. Trends. Endocrinol. Metab. 14, 44-50.
119. Régina A., Jodoin J., Khoueir P., et al. (2004). Down-regulation of caveolin-1 in glioma vasculature: modulation by radiotherapy. J. Neurosci. Res. 75, 291-299.
120. Razani B., Woodman S. E., Lisanti M. P. (2002). Caveolae: from cell biology to animal physiology. Pharmacol. Rev. 54, 431-467.
121. Liu P., Rudick M., Anderson R. G. (2002). Multiple functions of caveolin-1. J. Biol. Chem. 277, 41,295-41,298.
122. Galbiati F., Volonte D., Engelman J. A., et al. (1998). Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17, 6633-6648.
123. Fiucci G., Ravid D., Reich R., Liscovitch M. (2002). Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21, 2365-2375.
124. Liu J., Wang X. B., Park D. S., Lisanti M. P. (2002). Caveolin-1 expression enhances endothelial capillary tubule formation. J. Biol. Chem. 277, 10,661-10,668.
125. Enslen H., Davis R. J. (2001). Regulation of MAP kinases by docking domains. Biol. Cell 93, 5-14.
126. Cohen A. W., Park D. S., Woodman S. E., et al. (2003). Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 284, C457-C474.
127. Mandell J. W., Hussaini I. M., Zecevic M., Weber M. J., VandenBerg S. R. (1998). In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol. 153, 1411-1423.
128. Lakka S. S., Jasti S. L., Gondi C., et al. (2002). Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21, 5601-5608.
129. Labrecque L., Royal I., Surprenant D. S., Patterson C., Gingras D., Beliveau R. (2003). Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol. Biol. Cell. 14, 334-347.
130. Bello L., Francolini M., Marthyn P., et al. (2001). alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49, 380-389.
131. Bello L., Lucini V., Giussani C., et al. (2003). IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery 52, 177-185.
132. Wild-Bode C., Weller M., Rimner A., Dichgans J., Wick W. (2001). Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 61, 2744-2750.
133. Wick W., Wick A., Schulz J. B., Dichgans J., Rodemann H. P., Weller M. (2002). Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res. 62, 1915-1919.
134. Qian L. W., Mizumoto K., Urashima T., et al. (2002). Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. Clin. Cancer Res. 8, 1223-1227.
135. Huang R. P., Fan Y., Boynton A. L. (1999). UV irradiation upregulates Egr-1 expression at transcription level. J. Cell Biochem. 73, 227-236.
136. Datta R., Taneja N., Sukhatme V. P., Qureshi S. A., Weichselbaum R., Kufe D. W. (1993). Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc. Natl. Acad. Sci. USA 90, 2419-2422.
137. Weichselbaum R. R., Hallahan D., Fuks Z., Kufe D. (1994). Radiation induction of immediate early genes: effectors of the radiation-stress response. Int. J. Radiat. Oncol. Biol. Phys. 30, 229-234.
138. Thiel G., Cibelli G. (2002). Regulation of life and death by the zinc finger transcription factor Egr-1. J. Cell Physiol. 193, 287-292.
139. Haas T. L., Stitelman D., Davis S. J., Apte S. S., Madri J. A. (1999). Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J. Biol. Chem. 274, 22,679-22,685.
140. Yamaguchi S., Yamaguchi M., Yatsuyanagi E., et al. (2002). Cyclic strain stimulates early growth response gene product 1-mediated expression of membrane type 1 matrix metalloproteinase in endothelium. Lab. Invest. 82, 949-956.
141. Hallahan D. E., Qu S., Geng L., et al. (2001). Radiation-mediated control of drug delivery. Am. J. Clin. Oncol. 24, 473-480.
142. Meineke V., Gilbertz K. P., Schilperoort K., et al. (2002). Ionizing radiation modulates cell surface integrin expression and adhesion of COLO-320 cells to collagen and fibronectin in vitro. Strahlenther. Onkol. 178, 709-714.
143. Heckmann M., Douwes K., Peter R., Degitz K. (1998). Vascular activation of adhesion molecule mRNA and cell surface expression by ionizing radiation. Exp. Cell Res. 238, 148-154.
144. Hallahan D., Geng L., Qu S., et al. (2003). Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3, 63-74.
145. Kiani M. F., Yuan H., Chen X., Smith L., Gaber M. W., Goetz D. J. (2002). Targeting microparticles to select tissue via radiation-induced upregulation of endothelial cell adhesion molecules. Pharm. Res. 19, 1317-1322.
146. Paris F., Fuks Z., Kang A., et al. (2001). Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297.
147. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. (2003). Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159.
148. Mirsky N., Krispel Y., Shoshany Y., Maltz L., Oron U. (2002). Promotion of angiogenesis by low energy laser irradiation. Antioxid. Redox. Signal. 4, 785-790.
149. Sonveaux P., Brouet A., Havaux X., et al. (2003). Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res. 63, 1012-1019.
150. Hast J., Schiffer I. B., Neugebauer B., et al. (2002). Angiogenesis and fibroblast proliferation precede formation of recurrent tumors after radiation therapy in nude mice. Anticancer Res. 22, 677-688.
151. Landuyt W., Ahmed B., Nuyts S., et al. (2001). In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int. J. Radiat. Oncol. Biol. Phys. 49, 443-450.
152. Griscelli F., Li H., Cheong C., et al. (2000). Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc. Natl. Acad. Sci. USA 97, 6698-6703.
153. Gorski D. H., Mauceri H. J., Salloum R. M., Halpern A., Seetharam S., Weichselbaum R. R. (2003). Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. Cancer Res. 63, 308-311.
154. Ning S., Laird D., Cherrington J. M., Knox S. J. (2002). The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res. 157, 45-51.
155. Hess C., Vuong V., Hegyi I., et al. (2001). Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer 85, 2010-2016.
156. Lamy S., Gingras D., Beliveau R. (2002). Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 62, 381-385.
157. Demeule M., Michaud-Levesque J., Annabi B., et al. (2002). Green tea catechins as novel antitumor and antiangiogenic compounds. Curr. Med. Chem. Anti.-Canc. Agents 2, 441-463.
158. Greenwald P., Clifford C. K., Milner J. A. (2001). Diet and cancer prevention. Eur. J. Cancer 2001. 37, 948-965.
159. Annabi B., Lee Y-T., Martel C., Pilorget A., Bahary J-P., Béliveau R. (2003). Radiation induced-tubulogenesis in endothelial cells is antagonized by the antiangiogenic properties of green tea polyphenol(-)epigallocatechin-3- gallate. Cancer Biol. Ther 2, 642-649.
160. Kinuya S., Kawashima A., Yokoyama K., et al. (2002). Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J. Nucl. Med. 43, 1084-1089.
161. Curran W. J. (2002). New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology 63, 29-38.
162. Dicker A. P., Williams T. L., Grant D. S. (2001). Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am. J. Clin. Oncol. 24, 438-442.
163. Prockop D. J. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276, 71-74.
164. Dennis J. E., Charbord P. (2002). Origin and differentiation of human and murine stroma. Stem. Cells 20, 205-214.
165. Bianco P., Gehron R. P. (2000). Marrow stromal stem cells. J. Clin. Invest. 105, 1663-1668.
166. Studeny M., Marini F. C., Champlin R. E., Zompetta C., Fidler I. J., Andreeff M. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62, 3603-3608.
167. Mezey E., Chandross K. J. (2000). Bone marrow: a possible alternative source of cells in the adult nervous system. Eur. J. Pharmacol. 405, 297-302.
168. Kopen G. C., Prockop D. J., Phinney D. G. (1999). Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc. Natl. Acad. Sci. USA 96, 10,711-10,716.
169. Annabi B., Lee Y. T., Turcotte S., et al. (2003). Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem. Cells 21, 337-347.
170. Reyes M., Dudek A., Jahagirdar B., Koodie L., Marker P. H., Verfaillie C. M. (2002). Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 109, 337-346.
171. Al-Khaldi A., Eliopoulos N., Martineau D., Lejeune L., Lachapelle K., Galipeau J. (2003). Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther. Apr. 10, 621-629.
172. Annabi B., Naud E., Lee Y. T., Eliopoulos N., Galipeau J. (2003). Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. J. Cell. Biochem, 91, 1146-1158.
173. Al-Khaldi A., Al-Sabti H., Galipeau J., Lachapelle K. (2003). Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann. Thorac. Surg. 75, 204-209.
174. Griscelli F., Li H., Bennaceur-Griscelli A., et al. (1998). Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. USA 95, 6367-6372.
175. Ma H. I., Lin S. Z., Chiang Y. H., et al. (2002). Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther. 9, 2-11.
176. Peroulis I., Jonas N., Saleh M. (2002). Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int. J. Cancer 97, 839-845.
177. Lal B., Indurti R. R., Couraud P. O., Goldstein G. W., Laterra J. (1994). Endothelial cell implantation and survival within experimental gliomas. Proc. Natl. Acad. Sci. USA 91, 9695-9699.
178. Quinonero J., Tchelingerian J. L., Vignais L., et al. (1997). Gene transfer to the central nervous system by transplantation of cerebral endothelial cells. Gene Ther. 4, 111-119.
179. Ojeifo J. O., Lee H. R., Rezza P., Su N., Zwiebel J. A. (2001). Endothelial cell-based systemic gene therapy of metastatic melanoma. Cancer Gene Ther. 8, 636-648.
180. De Bouard S., Guillamo J. S., Christov C., et al. (2003). Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum. Gene Ther. 14, 883-895.
181. Takano S., Tsuboi K., Tomono Y., Mitsui Y., Nose T. (2000). Tissue factor, osteopontin alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br. J. Cancer 82, 1967-1973.
182. Schaefer L. K., Ren Z., Fuller G. N., Schaefer T. S. (2002). Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21, 2058-2065.